Jame Abraham: Continued Investment and Focus on Cancer Research Will Save Lives
Jame Abraham, Chairman and Professor at the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post on LinkedIn by BioKnow, adding:
“Cancer treatment is far from perfect – continued investment and focus on cancer research from pharma and government will save lives!
Lung Cancer and Breast Cancer trials lead the pack!”
Quoting BioKnow’s post:
“Clinical Trials Are Booming – Here’s What’s Hot.
2024 smashed records in clinical research:
4,903 industry-sponsored trials wrapped up worldwide – a 14.2% jump over 2023, per the latest Trialtrove analysis from Citeline.
Therapeutic Areas Leading the Charge:
- Oncology: Still the undisputed king with 1,466 completed trials
- Autoimmune and Inflammatory Diseases: On a roll with 828 trials
- CNS (Central Nervous System): Close behind at 811 trials, fueled by mental health and neurodegeneration RandD
Top Disease Areas by Trial Volume:
- Non-Small Cell Lung Cancer (NSCLC) is back at #1 with 242 trials
- Breast Cancer surged from 5th to 2nd – massive momentum
- Type 2 Diabetes remains a top focus
- COVID-19 fell from its peak, now at 4th
- Obesity and Pancreatic Cancer cracked the top 10
- Pancreatic cancer trials shot up 75% year-over-year!
And in oncology…
- Non-Hodgkin’s Lymphoma
- Head and Neck Cancer
- Pancreatic Cancer
…are now commanding serious attention and climbing the ranks fast.
Why It Matters
Clinical R&D is pivoting hard:
- From pandemic response,
- To chronic illness, rare cancers, and lifestyle-driven disease
With trial volume at an all-time high, the battle for late-phase innovation is heating up. The industry is moving faster, deeper, and more strategically.
Source: Citeline (Trialtrove Data)
Credit: Maryam Daneshpour.”
Ashok Sebastian Komaranchath, Consultant Medical Oncologist and Clinical Lead for Oncology Services at Burjeel Cancer Institute, Oman, shared Jame Abraham’s post, adding:
“This is why I love oncology..nearly every day there is a new discovery… new research, new molecules and new hope where there was none just a few years ago.”
More posts featuring Jame Abraham.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023